Breaking News Instant updates and real-time market news.

PCRX

Pacira

$48.65

1.25 (2.64%)

06:23
03/21/17
03/21
06:23
03/21/17
06:23

Pacira price target raised to $59 from $54 at Barclays

Barclays analyst Douglas Tsao raised his price target for Pacira Pharmaceuticals to $59 saying he left last week's American Academy of Orthopaedic Surgeons conference with increased confidence that the company's Exparel will sustain its recent commercial momentum. The analyst expects the pain treatment's sales will double in the coming years. He keeps an Overweight rating on Pacira.

PCRX Pacira
$48.65

1.25 (2.64%)

03/14/17
PIPR
03/14/17
NO CHANGE
Target $60
PIPR
Overweight
Piper more confident in Pacira after surgeon survey
Piper Jaffray analyst David Amsellem says his firm's survey of 29 orthopedic surgeons reinforces his confidence that Pacira Pharmaceuticals will be able to drive sustainable long-term volume growth for Exparel. Out of the 29 respondents, 83% noted that the data from the total knee arthroplasty study would result in them viewing Exparel's efficacy profile at least slightly more favorably, Amsellem tells investors in a research note. He believes Pacira is trading at an attractive risk/reward profile and reiterates an Overweight rating on the name with a $60 price target.
03/02/17
03/02/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Kite Pharma (KITE) downgraded to Neutral from Buy at Citi with analyst Robyn Karnauskas saying this week's rally on the "strong data" price a lot of value into the shares. The analyst expects approval of axicabtagene and estimates worldwide peak sales of $1.7B, but sees little share upside from the pipeline in the near-term. She raised her price target for Kite shares to $87 from $62. 2. Apache (APA) downgraded to Underweight from Equal Weight at Barclays with analyst Thomas Driscoll saying he expects the company's 2018 oil volumes to fall below 2016 levels. He cut his price target for the shares to $50 from $56. 3. American Eagle (AEO) downgraded to Neutral from Buy at BofA/Merrill with analyst Stephen Albert citing disappointing first quarter comparable-store sales guidance. 4. TripAdvisor (TRIP) downgraded to Neutral from Overweight at Piper Jaffray with analyst Michael Olson saying estimates may move lower as the company potentially increases investment in re-education. Olson thinks TripAdvisor shares may be range-bound through the remainder of the year and he lowered his price target for the stock to $47 from $60. 5. Pacira (PCRX) downgraded to Sell from Neutral at Janney Capital with analyst Ken Trbovich stating that its guidance suggests no meaningful change in the outlook for Exparel sales this year. While the company also announced positive results from its Phase 4 study of Exparel in total knee replacement surgery, it may take "years" for the company to fully exploit this commercially, said Trbovich, who raised his fair value estimate on the stock to $38 from $34. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/02/17
JANY
03/02/17
DOWNGRADE
Target $38
JANY
Sell
Pacira downgraded to Sell from Neutral at Janney Capital
Janney Capital analyst Ken Trbovich downgraded Pacira to Sell from Neutral, statin that its guidance suggests no meaningful change in the outlook for Exparel sales this year. While the company also announced positive results from its Phase 4 study of Exparel in total knee replacement surgery, it may take "years" for the company to fully exploit this commercially, said Trbovich, who raised his fair value estimate on the stock to $38 from $34.
03/02/17
JEFF
03/02/17
NO CHANGE
Target $60
JEFF
Buy
Pacira price target raised to $60 from $53 at Jefferies
Jefferies analyst David Steinberg raised his price target for Pacira Pharmaceuticals to $60 saying the "much anticipated" and positive total knee arthroplasty study readout should "help considerably" with hospital payers. Pacira "looks to be playing offense in 2017," the analyst writes. He keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

MRK

Merck

$64.16

0.375 (0.59%)

11:25
05/22/17
05/22
11:25
05/22/17
11:25
Hot Stocks
Merck says Phase 2 study results warrant continued evaluation of MK-7264 »

Merck announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 27

    May

  • 31

    May

  • 02

    Jun

  • 05

    Jun

  • 09

    Jun

  • 14

    Jun

LC

LendingClub

$5.92

0.26 (4.59%)

, ONDK

On Deck Capital

$3.71

0.32 (9.44%)

11:23
05/22/17
05/22
11:23
05/22/17
11:23
Periodicals
Online lendeers attract bond buyers, WSJ says »

According to…

LC

LendingClub

$5.92

0.26 (4.59%)

ONDK

On Deck Capital

$3.71

0.32 (9.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

MGM

MGM Resorts

$31.66

0.41 (1.31%)

11:20
05/22/17
05/22
11:20
05/22/17
11:20
Options
Notable option blocks in MGM »

Notable option blocks in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

11:17
05/22/17
05/22
11:17
05/22/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
05/22/17
05/22
11:16
05/22/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTBC

Medical Transcription Billing

$1.90

0.02 (1.06%)

11:15
05/22/17
05/22
11:15
05/22/17
11:15
Hot Stocks
MTBC jumps after announcing releases of app for smartphones »

Earlier today, MTBC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
05/22/17
05/22
11:15
05/22/17
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

11:15
05/22/17
05/22
11:15
05/22/17
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

XOM

Exxon Mobil

$82.08

0.147 (0.18%)

11:13
05/22/17
05/22
11:13
05/22/17
11:13
Hot Stocks
Exxon Mobil completes polyethylene lines at Texas plant »

ExxonMobil Chemical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

XOP

SPDR Oil Exploration and Production Fund

$35.37

-0.15 (-0.42%)

11:10
05/22/17
05/22
11:10
05/22/17
11:10
Options
Upside call buying in SPDR Oil Exploration and Production ETF »

Upside call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:10
05/22/17
05/22
11:10
05/22/17
11:10
General news
Treasury announced a $55 B 4-week bill auction for Tuesday »

Treasury announced a $55…

ORBK

Orbotech

$36.72

0.35 (0.96%)

11:09
05/22/17
05/22
11:09
05/22/17
11:09
Hot Stocks
Orbotech sinks after disclosing criminal probe by Israel Tax Authority »

Orbotech earlier today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 24

    May

AVY

Avery Dennison

$83.18

0.42 (0.51%)

11:09
05/22/17
05/22
11:09
05/22/17
11:09
Hot Stocks
Avery Dennison acquires Finesse Medical »

Avery Dennison…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORBK

Orbotech

$36.72

0.35 (0.96%)

11:08
05/22/17
05/22
11:08
05/22/17
11:08
Downgrade
Orbotech rating change  »

Orbotech downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 24

    May

RPT

Ramco-Gershenson

$12.75

-0.16 (-1.24%)

11:08
05/22/17
05/22
11:08
05/22/17
11:08
Conference/Events
Ramco-Gershenson management to meet with Jefferies »

Meeting to be held in Las…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

AVT

Avnet

$36.98

-0.1099 (-0.30%)

11:06
05/22/17
05/22
11:06
05/22/17
11:06
Hot Stocks
Avnet named exclusive global distributor for Silego Technology »

Avnet and Silego…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:05
05/22/17
05/22
11:05
05/22/17
11:05
General news
4-Week Bill Announcement Offering Amount data reported »

4-Week Bill Announcement…

RARX

RA Pharmaceuticals

$24.62

-0.32 (-1.28%)

11:04
05/22/17
05/22
11:04
05/22/17
11:04
Conference/Events
RA Pharmaceuticals management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

  • 24

    May

  • 25

    May

  • 22

    Jun

BBRY

BlackBerry

$10.38

0.27 (2.67%)

11:00
05/22/17
05/22
11:00
05/22/17
11:00
Options
Blackberry calls active as the rally continues »

Blackberry calls active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

QUOT

Quotient Technology

$11.30

0.05 (0.44%)

10:58
05/22/17
05/22
10:58
05/22/17
10:58
Conference/Events
Quotient Technology management to meet with Maxim »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

QUOT

Quotient Technology

$11.30

0.05 (0.44%)

10:57
05/22/17
05/22
10:57
05/22/17
10:57
Conference/Events
Quotient Technology management to meet with Loop »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

RHHBY

Roche

$34.30

0.495 (1.46%)

10:57
05/22/17
05/22
10:57
05/22/17
10:57
Hot Stocks
FDA approves Roche's Actemra for giant cell arteritis »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 06

    Jun

  • 26

    Jun

PQ

PetroQuest

$2.42

0.1285 (5.61%)

10:56
05/22/17
05/22
10:56
05/22/17
10:56
Conference/Events
PetroQuest management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 25

    May

C

Citi

$60.95

-0.15 (-0.25%)

10:53
05/22/17
05/22
10:53
05/22/17
10:53
Hot Stocks
Citi releases statement on settlement with DOJ over BUSA »

Citi issued the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 25

    Jul

PLNT

Planet Fitness

$20.81

0.13 (0.63%)

10:51
05/22/17
05/22
10:51
05/22/17
10:51
Conference/Events
Planet Fitness management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 20

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.